Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Dec. 2023, Evoke Pharmaspent€0.00 Mil on purchasing property, plant, equipment.
It gained€0.00 Mil from selling property, plant, and equipment.
It spent€0.00 Mil on purchasing business.
It gained€0.00 Mil from selling business.
It spent€0.00 Mil on purchasing investments.
It gained€0.00 Mil from selling investments.
It paid€0.00Mil for net Intangibles purchase and sale.
And it paid€0.00 Mil for other investing activities.
In all, Evoke Pharmagained€0.00 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Dec. 2023.
Evoke Pharma Cash Flow from Investing Historical Data
The historical data trend for Evoke Pharma's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Evoke Pharma's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoke Pharma (STU:EV00) Cash Flow from Investing Explanation
Evoke Pharma's purchase of property, plant, equipment for the
three
months ended in Dec. 2023 was €0.00 Mil. It means Evoke Pharma spent €0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Evoke Pharma's sale of property, plant, equipment for the
three
months ended in Dec. 2023 was €0.00 Mil. It means Evoke Pharma gained €0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Evoke Pharma's purchase of business for the
three
months ended in Dec. 2023 was €0.00 Mil. It means Evoke Pharma spent €0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Evoke Pharma's sale of business for the
three
months ended in Dec. 2023 was €0.00 Mil. It means Evoke Pharma gained €0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Evoke Pharma's purchase of investment for the
three
months ended in Dec. 2023 was €0.00 Mil. It means Evoke Pharma spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Evoke Pharma's sale of investment for the
three
months ended in Dec. 2023 was €0.00 Mil. It means Evoke Pharma gained €0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Evoke Pharma's net Intangibles purchase and sale for the
three
months ended in Dec. 2023 was €0.00 Mil.
It means Evoke Pharma paid €0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Evoke Pharma's cash from discontinued investing activities for the
three
months ended in Dec. 2023 was 0.00 Mil.
It means Evoke Pharma paid €0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Evoke Pharma's cash from other investing activities for the
three
months ended in Dec. 2023 was €0.00 Mil.
It means Evoke Pharma paid €0.00 Mil for other investing activities.
Evoke Pharma Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Evoke Pharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:EV00 has been successfully added to your 